Base de données sur les brevets canadiens

Page des revendications

---

Numéro de document de brevet: 2610755

(54) Titre anglais: CONTROLLED RELEASE OF A DRUG THROUGH SKIN ON THE BASIS OF A TOPICAL COMPOSITION COMPRISING A DRUG, A FILM-FORMING SILICONE AND AT LEAST ONE VOLATILE SOLVENT

(54) Titre français: METHODE DE LIBERATION CONTROLEE D'UN MEDICAMENT A TRAVERS LA PEAU

---

Revendications:

Nota : Les revendications sont présentées dans la langue officielle dans laquelle elles ont été soumises.


16
CLAIMS

1. A method for the controlled release of a drug through skin, which
method comprises topically administering a composition that comprises at least

one solubilized drug, a film-forming silicone, and at least one volatile
solvent.

2. The method of claim 1, wherein the drug is administered at a
dosage that is lower than the dosage used for compositions comprising the
same drug, but free of the film-forming silicone and the volatile solvent.

3. The method of claim 1, wherein the composition comprises two
drugs.

4. The method of claim 1, wherein the composition comprises
solubilized vitamin D or a vitamin D analogue.

5. The method of claim 4, wherein the vitamin D analogue is selected
from the group consisting of calcitriol, calcipotriol, doxercalciferol,
secalcitol,
maxacalcitol, seocalcitol, tacalcitol, paricalcitol, falecalcitriole,
1.alpha.,24S-
dihydroxy-vitamine D2, 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-
phenyl)-methoxy)-methyl]-9,10-seco-pregna-(Z),7(E),10(19)-triene and mixture
thereof.

6. The method of claim 5, wherein the vitamin D analogue is
calcitriol.

7. The method of claim 1, wherein the composition comprises a
solubilized corticosteroid.

8. The method of claim 7, wherein the corticosteroid is selected from
the group consisting of betamethasone, clobetasol, clobetasone,
desoximethasone, diflucortolon, diflorasone, fluocinonide, flumethasone,


17
fluocinolon, fluticasone, fluprednidene, halcinonide, hydrocortisone,
momethasone, triamcinolon, pharmaceutically acceptable esters or acetonides
thereof, and mixtures thereof.

9. The method of claim 7, wherein the esters or acétonides are
selected from the group consisting of 17-valerate, 17-propionate, 17,21-
dipropionate, acetonide, acetonide-21-N-benzoyl-2-methyl-.beta.-alaninate,
acetonide-21-(3,3-dimethylbutyrate) and 17-butyrate.

10. The method of claim 7, wherein the corticosteroid is clobetasol-17-
propionate.

11. The method of claim 1, wherein the volatile solvent is selected
from the group consisting of alkanols, alkylglycols, alkylketones and/or alkyl

esters wherein the alkyl moieties contain from 1 to 6 carbon atoms.

12. The method of claim 11, wherein the volatile solvent is ethanol.

13. The method of claim 1, wherein the film-forming silicone
comprises at least one polyorganosiloxane elastomer.

14. The method of claim 13, wherein the polyorganosiloxane
elastomer is present in a least one volatile silicone oil that is a linear or
cyclic
polyorganosiloxane oil having 2 to 10 silicium atoms.

15. The method of claim 1, wherein the silicone is at a concentration
of 20 to 90% weight based on the total weight of the composition.

16. The method of claim 1, wherein the solvent is at a concentration of
1 to 50% weight based on the total weight of the composition.


18
17. The method of claim 1, wherein the composition is in form of a
cream, a gel or an ointment.

18. The method of claim 1, wherein the composition is substantially
free of water.

19. The method of claim 1, wherein the composition comprises :
- isopropyl palmitate
- cyclopentasiloxane
-cyclomethicone 5/dimethicone crosspolymer
-calcitriol
-clobetasol-1 7- proprionate
-ethanol.

20. The method of claim 19, wherein the composition comprises, in
weight/weight of the composition:
- isopropyl palmitate 0.5-2%
- cyclopentasiloxane 10-20%
-cyclomethicone 5/dimethicone crosspolymer 70-80%
-calcitriol 0.0001-0.0005%
-clobetasol-17-proprionate 0.01-0.05%
-ethanol 5-10%.
21.Method of administering to a host a composition according to claims 1 to
20.

22. Method of treating skin disorders using a composition according to
claims 1 to 20.

23. Method of treatment according to claim 22, wherein the skin disorder is
psoriasis.